DGIdb - VELIPARIB Drug Record

VELIPARIB chembl:CHEMBL506871 Antineoplastic

Alternate Names:

ABT-888
VELIPARIB
PARP-1 INHIBITOR ABT-888
ABT 888
2-[(R)-2-METHYLPYRROLIDIN-2-YL]-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
(2R)-2-(7-CARBAMOYL-1H-BENZIMIDAZOL-2-YL)-2-METHYLPYRROLIDINIUM
2-((2R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
pubchem.compound:11960529
drugbank:07232
chembl:CHEMBL506871
chemidplus:912444-00-9

Drug Info:

Pharmaceutical Developer	Active Biochem
Source Reported Drug Name(s)	Veliparib/ABT-888
Drug Class	PARP Inhibitor
Drug Class	Small molecule inhibitor
Drug Categories	therapeutic uses
Drug Categories	poly(adp-ribose) polymerase inhibitors
Drug Categories	pharmacologic actions
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	heterocyclic compounds, 2-ring
Drug Categories	heterocyclic compounds
Drug Categories	enzyme inhibitors
Drug Categories	chemical actions and uses
Drug Categories	antineoplastic agents
Drug Groups	investigational
Drug Type	small molecule
Drug Categories	heterocyclic compounds, fused-ring

(8 More Sources)

Publications:

Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Patel et al., 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells., Proc. Natl. Acad. Sci. U.S.A.
Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.
Pishvaian MJ et al., 2020, A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer., Clin Cancer Res
Pietanza MC et al., 2018, Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer., J Clin Oncol
Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
Shen J et al., 2015, ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors., Cancer Discov

VELIPARIB PARP1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Reported Cancer Type Prostate

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
VELIPARIB PARP2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Direct Interaction yes

Notes

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
VELIPARIB PARP3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Publications:

VELIPARIB BRCA1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

Publications:

Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.

Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.

LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.

VELIPARIB MET

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

Publications:

Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.

VELIPARIB BRCA2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Phase II

Publications:

O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer

Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.

LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.

VELIPARIB ATM

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type stomach cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

Publications:

Patel et al., 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells., Proc. Natl. Acad. Sci. U.S.A.

Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.

Pishvaian MJ et al., 2020, A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer., Clin Cancer Res

VELIPARIB STAG2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell culture

Publications:

Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.

Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

VELIPARIB ARID1A

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

Publications:

Shen J et al., 2015, ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors., Cancer Discov
VELIPARIB PTEN

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Veliparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Publications:
VELIPARIB ATR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB07232
- Version: 5.1.7
Alternate Names:

VELIPARIB DrugBank Drug Name

912444-00-9 CAS Number

Drug Info:

Drug Type small molecule

Drug Groups investigational

Drug Categories antineoplastic agents

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
MyCancerGenome: VELIPARIB
- Version: 20-Jun-2017
Alternate Names:

ABT-888 Development Name

VELIPARIB Generic Name

Drug Info:

Drug Class Small molecule inhibitor

Publications:
CancerCommons: ABT-888
- Version: 25-July-2013
Alternate Names:

2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name

11960529 PubChem Drug ID

Veliparib Drug Trade Name

Drug Info:

Drug Class PARP Inhibitor

Source Reported Drug Name(s) Veliparib/ABT-888

Pharmaceutical Developer Active Biochem

Publications:

JAX-CKB: Veliparib

Version: 15-September-2020

Alternate Names:

Drug Info:

Publications:

Shen J et al., 2015, ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors., Cancer Discov

Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.

TALC: VELIPARIB
- Version: 12-May-2016
Alternate Names:

VELIPARIB Primary Drug Name

VELIPARIB Drug Generic Name

ABT-888 Drug Synonym

Drug Info:

Publications:
TTD: ABT-888
- Version: 2020.06.01
Alternate Names:

D0Q7UD TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL506871
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: VELIPARIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: VELIPARIB
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: VELIPARIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL506871
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
CGI: Veliparib
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	PARP 1, 2 and 3 inhibitor
Reported Cancer Type	Prostate

combination therapy	Veliparib;Cisplatin
Drug family	PARP inhibitor;Chemotherapy
Alteration	BRCA1:.

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	prostate cancer
Response Type	sensitive
Approval Status	Phase II

Indication/Tumor Type	stomach cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive
Approval Status	Preclinical - Cell culture

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

combination therapy	AZD6482 + Veliparib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide	PubChem Drug Name
11960529	PubChem Drug ID
Veliparib	Drug Trade Name

VELIPARIB	Primary Drug Name
VELIPARIB	Drug Generic Name
ABT-888	Drug Synonym

VELIPARIB	DrugBank Drug Name
912444-00-9	CAS Number

VELIPARIB Drug Record

VELIPARIB chembl:CHEMBL506871 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PARP 1, 2 and 3 inhibitor Reported Cancer Type Prostate

Publications: Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PARP 1, 2 and 3 inhibitor Direct Interaction yes Notes

Publications: Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Publications:

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Veliparib;Cisplatin Drug family PARP inhibitor;Chemotherapy Alteration BRCA1:.

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive Approval Status Preclinical

Publications: Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type prostate cancer Response Type sensitive Approval Status Phase II

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type stomach cancer Response Type sensitive Approval Status Preclinical - Cell line xenograft

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type glioblastoma multiforme Response Type sensitive Approval Status Preclinical - Cell culture

Publications: Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther. Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

Publications: Shen J et al., 2015, ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors., Cancer Discov

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD6482 + Veliparib Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

DrugBank: DB07232

Alternate Names: VELIPARIB DrugBank Drug Name 912444-00-9 CAS Number

Drug Info: Drug Type small molecule Drug Groups investigational Drug Categories antineoplastic agents

Publications: Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

MyCancerGenome: VELIPARIB

Alternate Names: ABT-888 Development Name VELIPARIB Generic Name

Drug Info: Drug Class Small molecule inhibitor

Publications:

CancerCommons: ABT-888

Alternate Names: 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name 11960529 PubChem Drug ID Veliparib Drug Trade Name

Drug Info: Drug Class PARP Inhibitor Source Reported Drug Name(s) Veliparib/ABT-888 Pharmaceutical Developer Active Biochem

Publications:

JAX-CKB: Veliparib

Alternate Names:

Drug Info:

TALC: VELIPARIB

Alternate Names: VELIPARIB Primary Drug Name VELIPARIB Drug Generic Name ABT-888 Drug Synonym

Drug Info:

Publications:

TTD: ABT-888

Alternate Names: D0Q7UD TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL506871

Alternate Names:

Drug Info:

Publications:

MyCancerGenomeClinicalTrial: VELIPARIB

Alternate Names:

Drug Info:

Publications:

ClearityFoundationBiomarkers: VELIPARIB

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: VELIPARIB

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL506871

Alternate Names:

Drug Info:

Publications:

CGI: Veliparib

Alternate Names:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Reported Cancer Type Prostate

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Direct Interaction yes

Notes

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

Publications:

Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Phase II

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type stomach cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell culture

Publications:

Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.

Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

Publications:

Shen J et al., 2015, ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors., Cancer Discov

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Veliparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Interaction Types & Directionality:

n/a

Alternate Names:

VELIPARIB DrugBank Drug Name

912444-00-9 CAS Number

Drug Info:

Drug Type small molecule

Drug Groups investigational

Drug Categories antineoplastic agents

Publications:

Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.

Alternate Names:

ABT-888 Development Name

VELIPARIB Generic Name

Drug Info:

Drug Class Small molecule inhibitor

Alternate Names:

2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name

11960529 PubChem Drug ID

Veliparib Drug Trade Name

Drug Info:

Drug Class PARP Inhibitor

Source Reported Drug Name(s) Veliparib/ABT-888

Pharmaceutical Developer Active Biochem

Alternate Names:

VELIPARIB Primary Drug Name

VELIPARIB Drug Generic Name

ABT-888 Drug Synonym

Alternate Names:

D0Q7UD TTD Drug ID